FIELD: biotechnology.
SUBSTANCE: invention relates to a bispecific antibody which binds to human TSLP, as well as to a monoclonal antibody which binds to human TSLP.
EFFECT: invention is effective for preventing or treating a TSLP-mediated disease.
15 cl, 14 dwg, 13 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE | 2018 |
|
RU2771384C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
